TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8406967
Drug: Post space
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post space preparation (both intervention groups)
Study: 3534902
Drug: 3 X
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 60 mg Eburnamonine per day (n = 25)
Study: 3534902
Drug: 1 X
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 X 60 mg Eburnamonine per day (n = 25)
Study: 18846701
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol (2.5 g/d)
Study: 18846701
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol (2.5 g/d)
Study: 15914133
Drug: Three gels
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three gels containing different amounts of N-9 per dose
Study: 12191837
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of glucose administered immediately before presentation of a word list
Study: 12191837
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of glucose administered immediately after presentation of a word list
Study: 12191837
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of glucose administered 15 min before learning the word list
Study: 2567265
Drug: SKF 94482
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF 94482 200 mg at 07:30
Study: 2567265
Drug: SKF 94482
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF 94482 200 mg at 17:30
Study: 2567265
Drug: SKF 94482
Normalized name: SKF-96365 free base
DrugBank: SKF-96365 free base (DB17054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKF 94482 200 mg at 21:30
Study: 28718527
Drug: Intralesional Verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks
Study: 28718527
Drug: Intralesional Hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional Hyaluronic Acid (0.8% highly purified sodium salt HA 16 mg/2 mL) weekly for 12 weeks
Study: 16820037
Drug: Bovine-derived xenograft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine-derived xenograft (BDX) in combination with collagen membrane (BG)
Study: 14559891
Drug: Aprepitant 375
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant 375 mg before cisplatin and 250 mg on days 2 to 5 (n = 35)
Study: 14559891
Drug: Aprepitant 125
Normalized name: aprepitant 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 125 mg before cisplatin and 80 mg on days 2 to 5 (n = 81)
Study: 10840297
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (10-day proton pump inhibitor-based triple therapy)
Study: 10840297
Drug: Dual antibiotic
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antibiotic therapy
Study: 8466096
Drug: Cetirizine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 10 mg, once daily (QD)
Study: 8466096
Drug: Terfenadine, 60
Normalized name: Terfenadine, 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 60 mg, twice daily (BID)
Study: 31801388
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate (10mg/ml)
Study: 31801388
Drug: Nepafenac (1mg/ml)
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nepafenac (1mg/ml)
Study: 31801388
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (prednisolone acetate and nepafenac)
Study: 26307570
Drug: CSL112 1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 1.7 g
Study: 26307570
Drug: CSL112 3.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 3.4 g
Study: 26307570
Drug: CSL112 6.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 6.8 g
Study: 26307570
Drug: CSL112 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (all doses)
Study: 20870337
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity cognitive therapy with nicotine replacement therapy (NRT)
Study: 20870337
Drug: High intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intensity cognitive therapy without nicotine replacement therapy (NRT)
Study: 19615208
Drug: Albumin administration
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin administration (100 ml 20% human albumin daily for 3 days)
Study: 19615208
Drug: Saline administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline administration (100 ml saline daily for 3 days)
Study: 15175800
Drug: Argatroban (ARG)
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban (ARG) at doses of 1.0, 2.0, or 3.0 microg/kg/min
Study: 15175800
Drug: Argatroban (ARG)
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban (ARG) at doses of 1.0, 2.0, or 3.0 microg/kg/min combined with VKA
Study: 15175800
Drug: Argatroban (ARG)
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban (ARG) at doses up to 2 microg/kg/min
Study: 3556129
Drug: 24 mEq
Normalized name: sodium chloride 0.124 MEQ/ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mEq of Slow-K given as 8 mEq/tablet tid
Study: 3556129
Drug: 30 mEq
Normalized name: Rum-K, 30 mEq/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mEq of K-Tab given as 10 mEq/tablet tid
Study: 23643522
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (40 mg/day)
Study: 23643522
Drug: Zinc +
Normalized name: GNP Cal Mag Zinc + D Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc + ALA supplementation (2 g/day flaxseed oil)
Study: 16537857
Drug: Bronchial hyperresponsiveness
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bronchial hyperresponsiveness (BHR) determined by methacholine challenge test with a provocative concentration producing a 20% fall in FEV(1) < or = 8 mg/mL.
Study: 16537857
Drug: Current diagnosed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current diagnosed asthma defined as previous physician‐diagnosed asthma and any asthma symptom within the past 12 months or currently receiving asthma medication.
Study: 14678209
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing with hydroxycitronellal plus sodium lauryl sulfate (SLS)
Study: 14678209
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing with hydroxycitronellal alone
Study: 10802474
Drug: Antibiotic solution
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic solution of neomycin and polymyxin B
Study: 10802474
Drug: 10% providone‐iodine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% providone‐iodine solution
Study: 10802474
Drug: Chlorhexidine gluconate
Normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gluconate solution
Study: 30724455
Drug: Lorcaserin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorcaserin treatment
Study: 12170046
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intravenous dexamethasone
Study: 24400953
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg oral dexamethasone
Study: 24400953
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 6 mg oral vs. 4 mg intravenous dexamethasone
Study: 19002481
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A injection (2-5 IU in 0.2-0.5 ml of saline)
Study: 30285891
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for IBS
Study: 30285891
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine treatment for IBS
Study: 22440275
Drug: VEGF Trap‐Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap‐Eye 2 mg
Study: 15970844
Drug: Low-dose hCG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hCG (200 IU intramuscular injection daily) after 100 mg CC
Study: 15970844
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg CC
Study: 9004107
Drug: Trandolapril 2
Normalized name: trandolapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 2 mg and placebo
Study: 9004107
Drug: Trandolapril 2
Normalized name: trandolapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 2 mg and indomethacin
Study: 26037274
Drug: 30% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% silver diammine fluoride (SDF) solution applied every 12 months
Study: 26037274
Drug: 30% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% silver diammine fluoride (SDF) solution applied three times at weekly intervals at baseline
Study: 26037274
Drug: 5% sodium
Normalized name: Dextrose 5% and 0.45% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sodium fluoride (NaF) varnish applied three times at weekly intervals at baseline
Study: 17586783
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 or 20 mg per day)
Study: 12127180
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment of insomnia
Study: 12127180
Drug: SDB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDB treatment (either nasal CPAP or nasal turbinates)
Study: 12127180
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment of insomnia (10 sleep hygiene recommendations)
Study: 12127180
Drug: SDB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDB treatment (nasal CPAP or nasal turbinates)
Study: 8569816
Drug: Flutrimazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutrimazole 1% solution, applied once daily for 4 weeks
Study: 8569816
Drug: Bifonazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole 1% solution, applied once daily for 4 weeks
Study: 2357865
Drug: Nicardipine hydrochloride
Normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine hydrochloride 0.5 mg/hr
Study: 2357865
Drug: Nicardipine hydrochloride
Normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine hydrochloride 1 mg/hr
Study: 2357865
Drug: Nicardipine hydrochloride
Normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine hydrochloride 2 mg/hr
Study: 2357865
Drug: Nicardipine hydrochloride
Normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine hydrochloride 4 mg/hr
Study: 2357865
Drug: Nicardipine hydrochloride
Normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine hydrochloride 5 mg/hr
Study: 2357865
Drug: Nicardipine hydrochloride
Normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine hydrochloride 8 mg/hr
Study: 2357865
Drug: Nicardipine hydrochloride
Normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine hydrochloride 2 mg/hr (severe hypertension)
Study: 6274571
Drug: Sham infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham infusions
Study: 6274571
Drug: Hydrocortisone infusions
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone infusions
Study: 6274571
Drug: Propranolol or
Normalized name: propranolol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol or indomethacin (additional treatment)
Study: 29251954
Drug: Internet-based affect-focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based affect-focused psychodynamic therapy (IPDT) for 10 weeks
Study: 27454410
Drug: Manualized Integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manualized Integrated Mood Management (MIMM); self-administered psychoeducation.
Study: 22467107
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin administration (16 IU)
Study: 10390212
Drug: Zanamivir (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir (600 mg) intravenously twice daily for 5 days
Study: 6365208
Drug: PF therapy
Normalized name: PF-05180999
DrugBank: PF-05180999 (DB14885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF therapy (1-phenylalanine mustard and 5-fluorouracil)
Study: 28114735
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg oral single dose) with glibenclamide (5 mg) and metformin (500 mg)
Study: 28114735
Drug: Carvedilol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25 mg oral single dose) in type 2 diabetes mellitus patients
Study: 26114297
Drug: Universal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal vaccination with one dose of 23-valent pneumococcal polysaccharide vaccine (PPV23)
Study: 23052228
Drug: zoledronate 5
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zoledronate 5 mg
Study: 20497640
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) + inhaled corticosteroids (ICS)
Study: 20497640
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) alone
Study: 8905424
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 72 mg/kg i.v. as a bolus, later 72 mg/kg over 12 h
Study: 1867454
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 50, 200, or 800 micrograms twice daily for 4 weeks
Study: 6347382
Drug: Clotrimazole (1%)
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole (1%) vaginal cream for seven days
Study: 6347382
Drug: Miconazole (2%)
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole (2%) vaginal cream for seven days
Study: 6347382
Drug: Clotrimazole (1%)
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clotrimazole (1%) vaginal cream
Study: 6347382
Drug: Miconazole (2%)
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole (2%) vaginal cream
Study: 31466807
Drug: Caregiving self‐management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiving self‐management support program (six bi‐weekly social support group sessions)
Study: 31466807
Drug: Telephone instructions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone instructions (three monthly instructions)
Study: 31576437
Drug: Na154 (154
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na154 (154 mmol/L sodium)
Study: 31576437
Drug: Na54 (54
Approvals — FDA: no, EMA: no, PMDA: no
Description: Na54 (54 mmol/L sodium)
Study: 28372526
Drug: Adjunctive metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive metformin (n=253)
Study: 25525759
Drug: Nanorap (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanorap (topical application of 2 g)
Study: 15497366
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg x kg(‐1) body mass, initial dose)
Study: 15497366
Drug: Caffeine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2.5 mg x kg(‐1) body mass, re-dose)
Study: 9083710
Drug: Famotidine (20-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (20-mg wafer)
Study: 9083710
Drug: Ranitidine (150-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150-mg tablet)
Study: 3574641
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg twice daily for 6 days
Study: 3574641
Drug: Ketanserin 20
Normalized name: ketanserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 20 mg for 2 weeks followed by 40 mg for 3 weeks
Study: 25422826
Drug: 5-mm short
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mm short implants
Study: 26438161
Drug: Anakinra (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (recombinant human interleukin‐1 receptor antagonist)
Study: 26392328
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DE) 150 mg alone
Study: 22946890
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DE) 150 mg with verapamil 120 mg immediate release given 1 hour before DE
Study: 22946890
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DE) 150 mg with verapamil 240 mg extended release
Study: 22946890
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DE) 150 mg after multiple verapamil dosing
Study: 22946890
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate (DE) 150 mg given 2 hours before verapamil
Study: 21455785
Drug: Low-Intensity Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Laser Therapy (LILT) using combined He-Ne and infrared lasers
Study: 19555315
Drug: Silymarin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (140 mg capsules, three times daily for 14 days)
Study: 15167084
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.60 mg/kg b.i.d.
Study: 11475920
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mgs/day)
Study: 2167452
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (500 mg/kg weekly to day 90, then monthly to day 360 after transplantation)
Study: 30149825
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy - Long (CBT-L)
Study: 30149825
Drug: Cognitive Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behaviour Therapy - Brief (CBT-B)
Study: 25187694
Drug: Intravitreal pegaptanib
Normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravitreal pegaptanib 0.3 mg
Study: 20714187
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab 1.25 mg
Study: 21210134
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose hCG (100 IU/day) with reduced r‐FSH (75 IU) after lead follicle reached 14 mm
Study: 21210134
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose hCG (200 IU/day) with discontinued r‐FSH after lead follicle reached 14 mm
Study: 19788471
Drug: Frovatriptan (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan (twice daily)
Study: 16499880
Drug: ABT-089 2
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-089 2 mg b.i.d.
Study: 16499880
Drug: ABT-089 4
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-089 4 mg b.i.d.
Study: 16499880
Drug: ABT-089 20
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-089 20 mg b.i.d.
Study: 9025426
Drug: Sequential single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential single electric breast pumping system
Study: 6835893
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg meptazinol
Study: 6835893
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg meptazinol
Study: 6835893
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg meptazinol
Study: 6835893
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of meptazinol
Study: 3514702
Drug: Bifonazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole 1% cream for 1 week
Study: 3514702
Drug: Bifonazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole 1% cream for 2 weeks
Study: 25541827
Drug: Sausalin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sausalin at a dose of 720 mg/day
Study: 25541827
Drug: Ornidazole at
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole at a dose of 1500 mg/day
Study: 20597951
Drug: Nicotinamide gel
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinamide gel 4%